Clear Scientific Presents at the Inaugural UC Summit on Methamphetamine: Advancing Research, Policy, and Public Health.

Cambridge, MA | April 2026

On April 17, 2026, Piercen Oliver PhD, VP of Research & Development of Clear Scientific Inc. presented at the Inaugural UC Summit on Methamphetamine: Advancing Research, Policy, and Public Health. 

The UC Summit is committed to being an outstanding beginning to building region wide efforts that address the challenges of intervention on methamphetamine use in Riverside County and throughout California.

Dr. Oliver’s talk centered around Treatment Innovation and described the chemistry, anticipated benefits, Phase 1 results and development status of CS-1103, Clear’s first-in-class sequestrant-based therapeutic for rapid treatment of methamphetamine intoxication.

About Clear Scientific 

Clear Scientific was co-founded in March 2019 by Professor George M. Whitesides of Harvard University with technology licensed from Massachusetts General Hospital and the University of Maryland. 

Clear Scientific is pioneering a new paradigm for treatment of conditions and diseases that involve an excess of specific compounds in the body. The company is developing highly selective, small molecule sequestrants that bind, inactivate, and rapidly clear these excess compounds from the body.  Clear Scientific receives funding from the National Institutes of Health (NIH) / National Institute on Drug Abuse (NIDA) and is working with their network of medical and academic professionals. 

About CS-1103 

CS-1103 is a first-in-class injectable small molecule sequestrant that binds and inactivates target compounds, rapidly reversing their effects and accelerating their clearance into urine. The Company is initially targeting methamphetamine, fentanyl and cocaine overdose, representing close to 95% of the drug fatalities in the US. Clear Scientific’s pipeline includes indications in central nervous system (CNS), metabolic diseases, amongst others. 

For more information, visit https://www.clearsci.com.